Regulatory
UniQure Files for FDA Approval of a Gene Therapy for Huntington’s Disease
After a bruising regulatory saga, the company submitted AMT-130 — a one-time, brain-delivered gene therapy that slowed disease progression over three years — for accelerated approval.